AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29273063
Drug: Inhaled Nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitrous Oxide (N2O) for 1 hour
Trial: 29273063
Drug: Fluoxetine (SSRI)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (SSRI) after N2O administration
Trial: 3356050
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine 50 mg
Trial: 19462722
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% 5 mL periprostatic infiltration
Trial: 15103312
Drug: losartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan treatment
Trial: 15103312
Drug: atenolol treatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol treatment
Trial: 12270853
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg followed by 75 mg daily)
Trial: 2403998
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg/day for 5 weeks
Trial: 2403998
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day for an additional 5 weeks
Trial: 31590702
Drug: Intravenous co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous co-amoxiclav (1 g of amoxicillin/200 mg of clavulanic acid)
Trial: 28192003
Drug: WEBCARE (online,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEBCARE (online, 12-weeks fixed, 6 lesson behavioral treatment based on problem solving therapy)
Trial: 21252084
Drug: Dexamethasone 0.1%
RxNorm normalized name: DEXAMETHASONE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1% drops four times daily for 1 week
Trial: 21252084
Drug: Hypromellose 0.3%
RxNorm normalized name: HYPROMELLOSE 0.3% GEL,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypromellose 0.3% drops four times daily for 1 week
Trial: 17762658
Drug: Valsartan 640
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 640 mg
Trial: 9391542
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg intravenously before chemotherapy)
Trial: 9391542
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg intravenously before chemotherapy, then every 8 hours for a total of 3 doses, plus 8 mg oral maintenance every 12 hours for 5 days)
Trial: 27836874
Drug: Cardiac resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronisation therapy (CRT) activated
Trial: 27836874
Drug: Cardiac resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronisation therapy (CRT) not activated
Trial: 12634969
Drug: 11C-metomidate PET
RxNorm normalized name: metomidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-metomidate PET imaging in group A (patients free of medication)
Trial: 12634969
Drug: 11C-metomidate PET
RxNorm normalized name: metomidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-metomidate PET imaging in group B (patients on medication)
Trial: 12634969
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with adrenal steroid inhibitors and chemotherapy
Trial: 9087160
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 micrograms aqueous nasal spray, administered twice daily for 2 weeks)
Trial: 9087160
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered twice daily for 2 weeks)
Trial: 17636088
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fluoxetine)
Trial: 8102913
Drug: Topical tiacrilast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tiacrilast 3% hydrogel
Trial: 2893778
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tulobuterol
Trial: 2893778
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg salbutamol
Trial: 2893778
Drug: Beta 2-agonists
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonists during strong contraction
Trial: 2893778
Drug: Continuous beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous beta 2-sympathomimetic treatment
Trial: 26271221
Drug: Water session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water session (200 ml water with breakfast, 750 ml water over 2 hours)
Trial: 14684712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Fluoxetine and Nortriptyline)
Trial: 11195032
Drug: Isotonic Ems
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic Ems salt solution
Trial: 9248588
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 50% glycerol
Trial: 9248588
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.5% bupivacaine
Trial: 3499246
Drug: 17/25/1 cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17/25/1 cold-adapted reassortant vaccine
Trial: 3499246
Drug: CR 59
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR 59 cold-adapted reassortant vaccine
Trial: 24035507
Drug: CPRmeter feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPRmeter feedback device (group G)
Trial: 19767092
Drug: Dose-dense paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-dense paclitaxel (80 mg/m²; 1-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=312
Trial: 19767092
Drug: Conventional regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen: Paclitaxel (180 mg/m²; 3-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=319
Trial: 17224859
Drug: Ultra-low-dose transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose transdermal estradiol (0.014 mg/d)
Trial: 15097957
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of narrowband UVB plus cream PUVA
Trial: 15097957
Drug: Cream PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream PUVA
Trial: 9525297
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy combined with anti-tuberculosis chemotherapy (n=17)
Trial: 9525297
Drug: Anti-tuberculosis chemotherapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis chemotherapy only (n=17)
Trial: 2979691
Drug: Caved-S two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caved-S two tablets twice daily
Trial: 2979691
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Caved-S + Ranitidine)
Trial: 2979691
Drug: Post-maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-maintenance therapy
Trial: 28958744
Drug: Caregiver worry
RxNorm normalized name: GLYCERIN 0.66 mg in 33 mL TOPICAL CREAM [IM SORRY FOR MY SKIN MASK - REVITALIZING]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver worry about medication side effects
Trial: 22965298
Drug: JASPER treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JASPER treatment (30 min, twice weekly for 12 weeks)
Trial: 22965298
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (30 h of ABA-based therapy per week)
Trial: 16958964
Drug: Regular pattern
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular pattern of trial medication intake
Trial: 16958964
Drug: Additional prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional prescribed medication
Trial: 1899797
Drug: Oxyquinoline ointment
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxyquinoline ointment
Trial: 1899797
Drug: Desitin or
RxNorm normalized name: Zinc Oxide 40% Topical application Ointment [DESITIN ORIGINAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desitin or A & D ointment (Control)
Trial: 26351971
Drug: Surfactant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (100 mg/kg) and Budesonide (0.25 mg/kg)
Trial: 26351971
Drug: Surfactant only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant only (100 mg/kg)
Trial: 24457276
Drug: Nicorandil (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (6 mg bolus injection before PCI and 6 mg/hour infusion for 24 hours)
Trial: 11559453
Drug: DRSP/EE (drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRSP/EE (drospirenone 3 mg and ethinyl estradiol 30 microg)
Trial: 9760324
Drug: Chicken broth
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken broth (CB: 109.5 mmol/l Na, 25.3 mmol/l K)
Trial: 9760324
Drug: Chicken noodle
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken noodle soup (Soup: 333.8 mmol/l Na, 13.7 mmol/l K)
Trial: 9760324
Drug: Carbohydrate‐electrolyte drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte drink (CE: 16.0 mmol/l Na, 3.3 mmol/l K)
Trial: 7826904
Drug: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil plus low-dose continuous prednisone)
Trial: 7826904
Drug: Combined chemoendocrine
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemoendocrine therapy (CMFp plus tamoxifen)
Trial: 3377464
Drug: Imipenem-cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (500 mg each) administered intravenously
Trial: 3377464
Drug: Imipenem-cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (500 mg each) administered intraperitoneally
Trial: 31233464
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m/dose)
Trial: 19235866
Drug: High-dose interferon-alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha-2b (10 MU) with ribavirin (RBV)
Trial: 19235866
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose interferon-alpha-2b (6 MU) with ribavirin (RBV)
Trial: 15961759
Drug: MEC plus
RxNorm normalized name: Ivomec Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEC plus lintuzumab (12 mg/m2)
Trial: 8749876
Drug: Isoproterenol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol administration during tilt test
Trial: 2702512
Drug: Inhaled lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lignocaine (40 mg)
Trial: 139671
Drug: Stanozolol (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol (an anabolic steroid), orally active, duration 4 months
Trial: 28031707
Drug: Budesonide/formoterol (B/F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (B/F) 320/9 μg, twice daily
Trial: 19371522
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide (100 microg)
Trial: 16896118
Drug: Levamisole (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (administered bimonthly)
Trial: 11491177
Drug: Influenza vaccines
RxNorm normalized name: Influenza vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccines (split product and surface antigen vaccines)
Trial: 11491177
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs (amantadine and rimantadine)
Trial: 11491177
Drug: New antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiviral agents targeting influenza neuraminidase
Trial: 9396433
Drug: Nadroparin (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (0.6 mL of 10,250 anti-Xa IU/mL)
Trial: 7970790
Drug: Skin end‐point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin end‐point titration based immunotherapy
Trial: 7970790
Drug: Prick testing
RxNorm normalized name: prickly pear fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prick testing based immunotherapy
Trial: 7970790
Drug: Scratch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scratch testing based immunotherapy
Trial: 27149496
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (BFT) during the temporary stoma period
Trial: 24275838
Drug: Valsartan-amlodipine (80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan-amlodipine (80/5 mg, then 160/10 mg)
Trial: 24275838
Drug: Atenolol-amlodipine (50/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol-amlodipine (50/5 mg, then 100/10 mg)
Trial: 12133124
Drug: Gradual benzodiazepine
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual benzodiazepine taper combined with cognitive-behavioural therapy
Trial: 12133124
Drug: Standard withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard withdrawal treatment
Trial: 10224354
Drug: rhuMAb‐E25 (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuMAb‐E25 (humanized monoclonal antibody against IgE)
Trial: 1691367
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg felodipine extended-release (ER) tablets
Trial: 523172
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg FK (synthetic enkephalin analogue) intramuscularly
Trial: 523172
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg FK intramuscularly
Trial: 523172
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg FK intramuscularly
Trial: 523172
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg betazole (placebo)
Trial: 27794193
Drug: Water sweetened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water sweetened with saccharin (5 mg/kg body weight)
Trial: 15598481
Drug: Wood creosote
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood creosote 135 mg (<or=5 doses/d)
Trial: 15598481
Drug: Loperamide 4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 4 mg (loading dose) followed by 2 mg (<or=8 mg/d) after each loose stool
Trial: 11386493
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and self-help manual
Trial: 8820889
Drug: Long, continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long, continuous contractions (CC)
Trial: 1317343
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg immune serum globulin
Trial: 1317343
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg immune serum globulin
Trial: 1317343
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (1 microgram/dose)
Trial: 1317343
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (0.5 micrograms/dose)
Trial: 1317343
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (0.25 micrograms/dose)
Trial: 29465549
Drug: Metabolic rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic rehabilitation program composed of aerobic and resisted exercises, performed for 12 weeks, in 3 weekly meetings of 60 minutes each.
Trial: 26982602
Drug: Pregabalin-Duloxetine Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin-Duloxetine Combination
Trial: 22865033
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline alternating with 5% dextrose at rate of 175 ml/h
Trial: 7846539
Drug: daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral etoposide/ifosfamide/cisplatin
Trial: 30580454
Drug: saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin (5 mg/day)
Trial: 29083936
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (50 mg losartan/12.5 mg HCTZ)
Trial: 29083936
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (100 mg losartan)
Trial: 24494695
Drug: Prior mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior mental health specialty treatment
Trial: 16317534
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/daily) for a maximum of 2 weeks
Trial: 16317534
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (diclofenac 100 mg/daily plus aescin 80 mg/daily)
Trial: 12883407
Drug: Propofol (target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (target-controlled infusion at concentrations of 2, 4, or 6 microg/ml)
Trial: 12883407
Drug: Remifentanil (increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (increasing concentrations from 0 to 7 ng/ml)
Trial: 8914115
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patches (placebo, low 7 mg/day, medium 14 mg/day, high 21 mg/day)
Trial: 8914115
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patches (all doses)
Trial: 1711261
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 500 ml hydroxyethylstarch 6% 0.62
Trial: 1711261
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 5000 IE unfractionated heparin
Trial: 6406947
Drug: Flutonidin (F)
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutonidin (F) 2 mg/day
Trial: 6406947
Drug: Clonidine (C)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (C) 0.3 mg/day
Trial: 30629889
Drug: Metformin (completers)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (completers)
Trial: 30629889
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance group
Trial: 29191561
Drug: Nexvax2 starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nexvax2 starting dose of 3μg in cohort 1
Trial: 29191561
Drug: Nexvax2 starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nexvax2 starting dose of 30μg in cohort 1
Trial: 29191561
Drug: Nexvax2 starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nexvax2 starting dose of 3μg in cohort 2
Trial: 29191561
Drug: Nexvax2 starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nexvax2 starting dose of 3μg in cohort 3
Trial: 29191561
Drug: Nexvax2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nexvax2 treatment at dose levels from 150μg to 900μg
Trial: 29191561
Drug: Nexvax2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nexvax2 treatment
Trial: 21903027
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus omega-3
Trial: 18670195
Drug: Formulation 13
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 13